Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10158670 | 0.71 | STS (0.42) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL30935381 | 0.70 | STS (0.39) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL5026108 | 0.66 | STS (0.64) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL4427945 | 0.66 | STS (0.59) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL25186921 | 0.65 | DRD2 (0.38) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL3464936 | 0.65 | CYP19A1 (0.35) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL21468547 | 0.64 | STS (0.62) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL19460607 | 0.64 | STS (0.40) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL8438305 | 0.63 | RXRA (0.40) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL30831415 | 0.63 | DGAT1 (0.45) | DRD2DRD3HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | DRD2 3595/4885DRD3 2627/4885HTR1D 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.